Montefiore Einstein Comprehensive Cancer Center

Researchers

• MKMarina Konopleva

Running trials

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07287150· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

  NCT06774027· University of California, San Francisco· Source

• Recruiting

  A Study of CTD402 in T-ALL/LBL Patients

  NCT07070219· Phase 1/2· Imviva Bio· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

  NCT06865339· Phase 2· Montefiore Medical Center· Source

• Recruiting

  Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

  NCT06745882· Phase 2· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

  NCT06533826· Phase 2· Ana C Garrido-Castro, MD· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  NCT06308588· Phase 1/2· M.D. Anderson Cancer Center· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source

• Recruiting

  Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  NCT06276491· Phase 1· Xencor, Inc.· Source

• Recruiting

  A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

  NCT06196203· Phase 2· Akeso· Source

• Recruiting

  Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

  NCT05423691· Phase 1· Cellenkos, Inc.· Source

• Active, not recruiting

  Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

  NCT05457010· Phase 1· Kite, A Gilead Company· Source

• Recruiting

  GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

  NCT04864054· Phase 1/2· Eureka Therapeutics Inc.· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Evolutionary Therapy for Rhabdomyosarcoma

  NCT04388839· Phase 2· H. Lee Moffitt Cancer Center and Research Institute· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Childhood cancers2 recruiting
• Colorectal cancer2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Prostate cancer2 recruiting
• Endometrial cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

  NCT05451849· Phase 1/2· TCR2 Therapeutics· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Myelodysplastic syndromes9 works · 2 trials